Navigation Links
3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
Date:12/4/2013

orward to testing our hypothesis that blocking FASN could provide a significant benefit in patients with solid tumors," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  Data from this trial will provide further information on the safety profile, dosing and selection of cancer types in anticipation of future studies for TVB-2640."

FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers. FASN inhibition reduced cell proliferation and induced apoptosis (cell death) in a dose-dependent manner and single-agent FASN inhibition both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts. In addition, 3-V has demonstrated potential synergy of its FASN inhibitors with cytotoxic agents.  

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The
3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
2. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
3. ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
4. 3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
5. Lilly Statement on Contribution to Indiana Biosciences Research Institute
6. Indiana Biosciences Research Institute Hits $50 Million Start-Up Funding Goal
7. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
10. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Ohio and CAMBRIDGE, Mass. ... Specialty Solutions and KEW Group, Inc. (KEW), a ... agreement for the two companies to make KEW,s ... oncology customers. KEW is a privately ... revolutionizing cancer care by empowering all oncologists to ...
(Date:9/29/2014)... , Sept. 29, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... accessories from Itamar Medical Ltd. (TASE: ITMR) ("Itamar ... has been cleared by the U.S. Food and ...
(Date:9/29/2014)... , Sept. 29, 2014 Avanir Pharmaceuticals, ... closing of its previously announced public offering of 20,930,000 ... to the underwriters, full exercise of their option to ... of $11.00 per share, before underwriting discounts. J.P. Morgan, ... joint book-running managers for the offering. Piper Jaffray ...
Breaking Medicine Technology:Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 2Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 4Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function 2Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function 3Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 3
... Inc., a leading provider of healthcare IT and medical billing ... prestigious 2010 Inc. 5000 list, a compendium of the most ... order to qualify for the Inc. 5000, companies such as ... exemplary four-year growth. Founded in 2005, this was the first ...
... Store announced today it has selected an integrated Omnicom team ... revamping its roster of agencies to include a new team ... and proven expertise in branding and direct response. The Omnicom ... includes Porter Novelli, Javelin Marketing Group and AdelphiEden.   ...
Cached Medicine Technology:ITelagen Named to Prestigious 2010 Inc. 5000 List of Fastest-Growing Companies 2The SCOOTER Store Partners With Branding Leader 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 Barbara Williamson ... her amazing memoir "An Extraordinary Life: Love, Sex ... β€œthe messiah of sex,” of the highly successful and ... 1960s and early β€˜70s, the couple started what became ... The clothing-optional, alternate-lifestyle Sandstone Retreat was outrageously popular, with ...
(Date:9/30/2014)... In a move that will ... capture and management functions for sponsors, Synergy Research ... (EDC) system. ClinCapture offers advanced out-of-the-box features that ... clinical trial data and avoid errors and duplications. ... the leading clinical research organization in the Russian ...
(Date:9/30/2014)... 2014 Computer Resources of America, ... based in New York City, has been awarded ... to transform, manage, and support the IT environment ... a leading provider of innovative services that enable ... The contract will cover the four NY-metro ...
(Date:9/30/2014)... September 30, 2014 Miraca Life Sciences ... present eight research posters at the annual meeting of ... will hold its Annual Scientific Meeting and Postgraduate Course ... hall, staff from Miraca Life Sciences will be at ... Clinical Case Challenge. , The research posters for ACG ...
(Date:9/30/2014)... Bibliomotion is proud to announce the release of ... Age by Frank Guglielmo and Sudhanshu Palsule ... apply their leadership coaching experience to introduce Social Leadership – ... behaviors that leaders must adopt in order to thrive in ... a review of The Social Leader in Dialogue Reviews. , ...
Breaking Medicine News(10 mins):Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3Health News:Synergy Research Group Opts for Clinovo 2Health News:Synergy Research Group Opts for Clinovo 3Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:Miraca Life Sciences Research Institute to Present Eight GI Pathology Research Studies at Annual Meeting of American College of Gastroenterologists 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6
... Will build upon Research, Care, Advocacy and Education Programs ... YORK, Jan. 29 The Trustees of the Huntington,s ... that Louise Vetter, currently CEO of the American Lung ... Chief Executive Officer, Monday, March 16. In her nine ...
... Mice whose fat cells were allowed to grow larger than fat ... diet, researchers at UT Southwestern Medical Center found in a new ... called collagen VI, which normally surrounds fat cells and limits how ... The findings appear online and in a future edition of ...
... (RA) remains unclear, bioactive proteins known as cytokines, particularly ... a major role in the disease by contributing to ... cytokine, has been thought to be critical for a ... deliver oxygen and nutrients to fetus. A new study ...
... North State Bancorp (OTC,Bulletin Board: NSBC) (the "Company"), ... of $687.6 million as of December 31, 2008,compared to ... an increase,of $140.1 million or 25.6%. , ... December 31, 2008 were $612.7,million and total loans were ...
... babies have complications, without ill effects, study finds , , THURSDAY, ... steroids to babies still in the womb can reduce their ... their growth the way multiple courses can, new research shows. ... of those given a second dose of steroids in utero ...
... Second Annual "For All the Ways You Care" ... of CaregivingWOONSOCKET, R.I., Jan. 29 CVS/pharmacy, the ... annual "For All the Ways You Care" contest ... http://www.newscom.com/cgi-bin/prnh/20090129/NE64371LOGO )CVS/pharmacy invites caregivers and ...
Cached Medicine News:Health News:Louise Vetter joins Huntington's Disease Society of America as new CEO 2Health News:Louise Vetter joins Huntington's Disease Society of America as new CEO 3Health News:UT Southwestern researchers identify protein that may explain 'healthy' obesity 2Health News:Process found to play role in rheumatoid arthritis could lead to new treatment 2Health News:North State Bancorp Reports Profitable 2008 2Health News:North State Bancorp Reports Profitable 2008 3Health News:North State Bancorp Reports Profitable 2008 4Health News:North State Bancorp Reports Profitable 2008 5Health News:North State Bancorp Reports Profitable 2008 6Health News:Additional Steroid Dose May Help Preemies 2Health News:Additional Steroid Dose May Help Preemies 3Health News:CVS/pharmacy Announces National Contest for Stories of Extraordinary Caregiving 2Health News:CVS/pharmacy Announces National Contest for Stories of Extraordinary Caregiving 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: